BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Skyline Diagnostics B.V. Establishes Research Collaboration With Janssen Pharmaceutica N.V.


7/6/2011 9:11:07 AM

ROTTERDAM, The Netherlands, July 6, 2011 /PRNewswire/ --


Skyline Diagnostics B.V. (Skyline), a biotechnology company focusing on development and marketing of gene signature-based diagnostic assays based in The Netherlands, today announced that it has signed a Research Agreement with Johnson & Johnson Pharmaceutical Research and Development division of Janssen Pharmaceutica N.V. (Janssen). Under the agreement Skyline, using its proprietary knowledge and technologies in the area of genetic profiling and bioinformatics will work with Janssen to generate and analyze diagnostic information related to the use of an undisclosed, marketed compound. Under the terms of the agreement, Skyline will receive R&D funding and could receive payments on the achievement of certain research milestones. Financial details of the agreement were not disclosed.

"We are very pleased with extension of this exciting companion diagnostic program," said Henk Viëtor, CEO of Skyline Diagnostics, "this collaboration will provide both companies the opportunity to develop a unique personalized medicine approach to help identify patients at increased risk of side effects."

AboutSkyline Diagnostics BV

Skyline Diagnostic with its headquarters in Rotterdam, The Netherlands, develops and markets array-based diagnostic tests using gene signatures for personalized medicine. The company has successfully translated several important scientific discoveries into diagnostics. These products, called Profilers, are based on gene expression and offer a high additional clinical value. Skyline Diagnostics' Profilers will provide the clinician in-depth insight in the prognosis of individual patients and facilitate the treatment decision making process. The company has built strong collaborations with leading scientists and has strategic alliances with industrial partners for distribution and manufacturing, including a 'Powered by Affymetrix' partnership.

Website: http://www.skyline-diagnostics.com

SOURCE Skyline Diagnostics B.V.



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES